The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance
Open accessAbstract
In Parkinson's disease (PD) and dementia with Lewy bodies (DLB) alpha-synuclein (alphaS) pathology is seen that displays a predictable topographic distribution. There are two staging/categorization systems, i.e. Braak's and McKeith's, currently in use for the assessment of alphaS pathology. The aim of these diagnostic strategies in pathology is, in addition to assess the stage/severity of pathology, to assess the probabilities of the related clinical symptomatology i.e. dementia and extrapyramidal symptoms (EPS). Herein, we assessed the applicability of these two staging/categorization systems and the frequency of dementia and EPS in a cohort of 226 alphaS-positive-subjects. These subject were selected from a large autopsy sample (n = 1,720), irrespective of the clinical presentation, based on the detection of alphaS-immunoreactivity (IR) in one of the most vulnerable nuclei; in the dorsal motor nucleus of vagus, substantia nigra and basal forebrain. The frequency of alphaS-IR lesions in this large cohort was 14% (248 out of 1,720). If applicable, each of the 226 subjects with all required material available was assigned a neuropathological stage/category of PD/DLB and finally the neuropathological data was analyzed in relation to dementia and EPS. 83% of subjects showed a distribution pattern of alphaS-IR that was compatible with the current staging/categorization systems. Around 55% of subjects with widespread alphaS pathology (Braak's PD stages 5-6) lacked clinical signs of dementia or EPS. Similarly, in respect to those subjects that fulfilled the McKeith criteria for diffuse neocortical category and displaying only mild concomitant Alzheimer's disease-related pathology, only 48% were demented and 54% displayed EPS. It is noteworthy that some subjects (17%) deviated from the suggested caudo-rostral propagation suggesting alternative routes of progression, perhaps due to concomitant diseases and genetic predisposition. In conclusion, our results do indeed confirm that current staging/categorization systems can readily be applied to most of the subjects with alphaS pathology. However, finding that around half of the subjects with abundant alphaS pathology remain neurologically intact is intriguing and raises the question whether we do assess the actual disease process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 10×
“Seventeen subjects were excluded due to lack of clinical information or inadequate amount of brain material required for the classiWcation as recommended by Mc Keith and Braak [4, 28], and thus ultimately, this study examined 226 subjects.”
BackgroundMethodResultInfluentialDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960 · cited 2×
“PD and DLB are distinguished as separate clinical entities and in 1996 the consortium of the DLB international workshop subdivided the neuropathological features of DLB into three categories: brainstem predominant, limbic and diVuse neocortical type [27].”
BackgroundAGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citationCaughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650 · cited 1×
“Many biophysical studies have suggested that it is a protoWbrillar form of S rather than the “mature” Wbrils that are responsible for the cell death [ 7 , 15, 36], and moreover, the Wbrillar form that is typically observed at autopsy may actually be a sign of a well functioning neuroprotection [31, 34].”
BackgroundSirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease
Outeiro, T. F., Kontopoulos, E., Altmann, S. M., Kufareva, I., Strathearn, K. E., Amore, A. M., Volk, C. B., Maxwell, M. M., Rochet, J.-C., McLean, P. J., et al. (2007) · Science · doi:10.1126/science.1143780 · Cited by 1,062
Where Does Parkinson Disease Pathology Begin in the Brain?
Del Tredici, K., Rüb, U., de Vos, R. A. I., Bohl, J. R. E., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.5.413 · Cited by 773
McKeith, I. G. (2004) · Europe PMC (PubMed Central) · Cited by 756
Hamilton, R. L. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00269.x · Cited by 754
Neuropathology of Cognitively Normal Elderly
Knopman, D. S., Parisi, J. E., Salviati, A., Floriach-Robert, M., Boeve, B. F., Ivnik, R. J., Smith, G. E., Dickson, D. W., Johnson, K. A., Petersen, L. E., et al. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.11.1087 · Cited by 674
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease
Hurtig, H. I., Trojanowski, J. Q., Galvin, J., Ewbank, D., Schmidt, M. L., Lee, V. M. Y., Clark, C. M., Glosser, G., Stern, M. B., Gollomp, S. M., et al. (2000) · Neurology · doi:10.1212/wnl.54.10.1916 · Cited by 601
Parkinson's Disease Society Brain Bank, London: overview and research.
Daniel, S. E., & Lees, A. J. (1993) · PubMed · Cited by 589
Cognitive status correlates with neuropathologic stage in Parkinson disease
Braak, H., Rüb, U., Jansen Steur, E. N. H., Del Tredici, K., & de Vos, R. A. I. (2005) · Neurology · doi:10.1212/01.wnl.0000158422.41380.82 · Cited by 560
Alzheimer neuropathologic alterations in aged cognitively normal subjects
Davis, D. G., Schmitt, F. A., Wekstein, D. R., & Markesbery, W. R. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199904000-00008 · Cited by 516 · cited 1×
“Some authors have emphasized their key causative role [1, 18, 21, 26], whereas others have reported that there may be abundant cortical pathology in non-demented PD patients [8] as well as in neurologically unimpaired subjects [ 10 , 24, 32].”
BackgroundIs there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease?
Goldberg, M. S., & Lansbury Jr, P. T. (2000) · Nature Cell Biology · doi:10.1038/35017124 · Cited by 458
Volles, M. J., & Lansbury, P. T. (2003) · Biochemistry · doi:10.1021/bi030086j · Cited by 433
Aggresomes Formed by α-Synuclein and Synphilin-1 Are Cytoprotective
Tanaka, M., Kim, Y. M., Lee, G., Junn, E., Iwatsubo, T., & Mouradian, M. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310994200 · Cited by 422
Kosaka, K., Yoshimura, M., Ikeda, K., & Budka, H. (1984) · PubMed · Cited by 401
Parkinson Disease Neuropathology: Later-Developing Dementia and Loss of the Levodopa Response
Apaydin, H., Ahlskog, J. E., Parisi, J. E., Boeve, B. F., & Dickson, D. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.1.102 · Cited by 399
Klunk, W. E., Price, J. C., Mathis, C. A., Tsopelas, N. D., Lopresti, B. J., Ziolko, S. K., Bi, W., Hoge, J. A., Cohen, A. D., Ikonomovic, M. D., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0730-07.2007 · Cited by 389
Mattila, P. M., Rinne, J. O., Helenius, H., Dickson, D. W., Röyttä, M., & Mattila, P. M. (2000) · Acta Neuropathologica · doi:10.1007/s004019900168 · Cited by 361
Alzheimer Disease With Amygdala Lewy Bodies: A Distinct Form of α-Synucleinopathy
Uchikado, H., Lin, W.-L., DeLucia, M. W., & Dickson, D. W. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000225908.90052.07 · Cited by 359
Bloch, A., Probst, A., Bissig, H., Adams, H., & Tolnay, M. (2006) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00727.x · Cited by 330
Benaroudj, N., & Goldberg, A. L. (2000) · Nature Cell Biology · doi:10.1038/35041081 · Cited by 328
α‐Synuclein pathology does not predict extrapyramidal symptoms or dementia
Parkkinen, L., Kauppinen, T., Pirttilä, T., Autere, J. M., & Alafuzoff, I. (2005) · Annals of Neurology · doi:10.1002/ana.20321 · Cited by 315
Self-citationLewy-body formation is an aggresome-related process: a hypothesis
Olanow, C. W., Perl, D. P., DeMartino, G. N., & McNaught, K. S. P. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00827-0 · Cited by 305
Bodner, R. A., Outeiro, T. F., Altmann, S., Maxwell, M. M., Cho, S. H., Hyman, B. T., McLean, P. J., Young, A. B., Housman, D. E., & Kazantsev, A. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511256103 · Cited by 256
Kövari, E., Gold, G., Herrmann, F. R., Canuto, A., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0705-2 · Cited by 228
Jellinger, K. A. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0725-y · Cited by 201
Lewy body cortical involvement may not always predict dementia in Parkinson's disease
Colosimo, C. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.7.852 · Cited by 200
α-Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals
Klos, K. J., Ahlskog, J. E., Josephs, K. A., Apaydın, H., Parisi, J. E., Boeve, B. F., DeLucia, M. W., & Dickson, D. W. (2006) · Neurology · doi:10.1212/01.wnl.0000204179.88955.fa · Cited by 127
Dementia with Lewy Bodies. A Distinct Non‐Alzheimer Dementia Syndrome?
Ince, P. G., Perry, E. K., & Morris, C. M. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00156.x · Cited by 123
Clinical and neuropathological correlates of Lewy body disease
Hishikawa, N., Hashizume, Y., Yoshida, M., & Sobue, G. (2003) · Acta Neuropathologica · doi:10.1007/s00401-002-0651-4 · Cited by 91
Pathology and Neurotransmitter Abnormalities of Dementia with Lewy Bodies
Duda, J. E. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000074677 · Cited by 80
Widespread and abundant α‐synuclein pathology in a neurologically unimpaired subject
Parkkinen, L., Pirttilä, T., Tervahauta, M., & Alafuzoff, I. I. (2005) · Neuropathology · doi:10.1111/j.1440-1789.2005.00644.x · Cited by 77
Self-citationLinking SIRT2 to Parkinson’s Disease
Garske, A. L., Smith, B. C., & Denu, J. M. (2007) · ACS Chemical Biology · doi:10.1021/cb700160d · Cited by 59
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972
Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats
Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., Wang, Z.-Y., Roybon, L., Melki, R., & Li, J.-Y. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1343-6 · Cited by 925
Arizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Sue, L. I., Vedders, L., Lue, L., White III, C. L., Akiyama, H., Caviness, J. N., Shill, H. A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0664-3 · Cited by 911
Metadata
- Authors
- Parkkinen, L., Pirttilä, T., & Alafuzoff, I.
- Venue
- Acta Neuropathologica
- Published
- 2008-02-23
- Volume
- 115
- Issue
- 4
- Pages
- 399-407
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2064284597
- Cited by
- 354
- References
- 38
- FWCI
- 17.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.